Programs

A balanced portfolio across longevity, oncology, and cardiometabolic medicine.

EvoPharma combines frontier biology with clinically validated pathways to create a diversified therapeutic strategy.

Developing therapies targeting biological mechanisms that influence healthspan, metabolic dysfunction, inflammation, and age-associated decline.

Developing next-generation cancer therapeutics using AI-guided molecular discovery, CRO synthesis, and rapid external biological validation.

Next-generation cholesterol regulation and cardiovascular risk reduction through PCSK9 pathway targeting.

Metabolic health programs focused on obesity, diabetes-related pathways, and cardiometabolic disease burden.

Lead molecules are advanced through staged external synthesis, characterization, and optimization.

External assays are planned for target engagement, cell-based activity, mechanism, early toxicity, ADME, and proof-of-concept studies.

Estimated outsourced development cost

AI discovery and computational design$10k–$100k for target analysis, molecule design, and candidate prioritization.

CRO chemistry optimization$100k–$500k for synthesis, analog generation, characterization, and quality control.

In vitro validation$100k–$500k for target engagement, cell-based efficacy, mechanism studies, and early toxicity assessment.

ADME and early safety$200k–$1M for metabolic stability, solubility, PK screening, and early safety profiling.

In vivo proof-of-concept$500k–$2M for disease models, dose optimization, biomarkers, and efficacy confirmation.